Balance Sheet
Accounts PayablesAccumulated ExpensesAssetsCapital LeasesCash & Current InvestmentsCash & EquivalentsCommon EquityCurrent AssetsCurrent LeasesLiabilities and Shareholders EquityNon-Current AssetsNon-Current Deffered RevenueOperating LeasesOther Non-Current AssetsOther Non-Current LiabilitiesPayablesPrepaid AssetsProperty, Plant & Equipment (Net)Retained EarningsShareholder's EquityShort term DebtTotal Current LiabilitiesTotal DebtTotal LiabilitiesTotal Non-Current Liabilities
Cash Flow Statement
Daily Values
Growth Metrics
Income Statement
Others
Ratios

Dare Bioscience (DARE) Non-Current Debt (2016)

Dare Bioscience (DARE) has disclosed Non-Current Debt for 4 consecutive years, with $4.4 million as the latest value for Q4 2016.

  • For the quarter ending Q4 2016, Non-Current Debt fell 64.97% year-over-year to $4.4 million, compared with a TTM value of $4.4 million through Dec 2016, down 64.97%, and an annual FY2016 reading of $4.4 million, down 64.97% over the prior year.
  • Non-Current Debt was $4.4 million for Q4 2016 at Dare Bioscience, down from $6.6 million in the prior quarter.
  • Across five years, Non-Current Debt topped out at $13.6 million in Q1 2015 and bottomed at $587000.0 in Q3 2014.
  • Average Non-Current Debt over 4 years is $7.2 million, with a median of $7.6 million recorded in 2016.
  • The sharpest move saw Non-Current Debt surged 1693.87% in 2015, then tumbled 64.97% in 2016.
  • Year by year, Non-Current Debt stood at $3.1 million in 2013, then crashed by 81.21% to $587000.0 in 2014, then skyrocketed by 2058.77% to $12.7 million in 2015, then crashed by 64.97% to $4.4 million in 2016.
  • Business Quant data shows Non-Current Debt for DARE at $4.4 million in Q4 2016, $6.6 million in Q3 2016, and $8.6 million in Q2 2016.